<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81866">
  <stage>Registered</stage>
  <submitdate>19/02/2007</submitdate>
  <approvaldate>19/06/2007</approvaldate>
  <actrnumber>ACTRN12607000330448</actrnumber>
  <trial_identification>
    <studytitle>The safety and efficacy of recombinant neuregulin-1 (rhNRG-1) in patients with stable chronic heart failure</studytitle>
    <scientifictitle>The safety and efficacy of recombinant neuregulin-1 (rhNRG-1) in patients with stable chronic heart failure</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous administration of recombinant Human neuregulin-1 (novel drug). 1.2 mcg/kg/day for 1 day then 2.4 mcg/kg/day intravenously for 10 days.</interventions>
    <comparator>No control arm.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Outcome:
To assess the safety of rhNRG-1 in patients with stable symptomatic chronic heart failure, as determined by the incidence and severity of adverse clinical events, new electrocardiographic and laboratory abnormalities</outcome>
      <timepoint>For 3 months after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Efficacy Outcome:
To assess the effect of rhNRG-1 on left ventricular function and remodeling as determined by change in Left ventricular ejection fraction(LVEF), Left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV), measured by MRI</outcome>
      <timepoint>Measured at 12 days and 3 months post-baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.To assess the effect of rhNRG-1 on acute haemodynamics (cardiac output, left and right heart filling pressures, pulmonary and systemic blood pressures, and systemic and pulmonary vascular resistance after single and repeated dosing.</outcome>
      <timepoint>With repeated measurements over the first 24 hours and also at day 12 and 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.To assess the effect of rh-NRG-1 on the following neuro-hormonal and immunological markers in blood:  noradrenaline, aldosterone,  endothelin-1, nt-proBNP, terminal propeptide of type III procollagen (PIIINP), highly sensitive c-reactive protein (hsCRP),Tumour necosis factor alpha (TNF alpha) and interleukin 6 (IL-6).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. To assess the effect of rh-NRG-1 on interstitial myocardial fibrosis as measured by magnetic resonance imaging</outcome>
      <timepoint>At day 12 and 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Written informed consent. Left ventricular systolic dysfunction (LVEF &lt; 40%) secondary to ischaemic heart disease or cardiomyopathyStable NYHA Class II or III symptomatic heart failurePatients established on ACEI/ARA and beta blocker with stable doses of these medications for the preceding 3 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>NYHA Class I or IV heart failureAcute myocardial infarction or unstable angina within 3 monthsCoronary artery revascularization or left ventricular remodeling surgery within preceding 3 monthsPatients awaiting coronary artery revascularisation or left ventricular remodeling surgeryImplanted pacemaker or defibrillatorChronic atrial fibrillation or flutterPrimary valvular heart diseaseHypertrophic or restrictive cardiomyopathyClaustrophobiaPregnancy or lactation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>26/02/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Peter Macdonald</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Zensun (Aust) Sci &amp; Tech Co., Ltd.</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Andrew Jabbour</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This will test the safety and efficacy of a new drug called recombinant human Neuregulin-1 in patients with chronic stable heart failure. We hope to establish that recombinant human Neuregulin-1 (rhNRG-1) can be administered safely and that its administration results in improved heart structure and function as measured by cardiac MRI at 12 days and 3 months.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress>Sydney NSW 2010</ethicaddress>
      <ethicapprovaldate>24/08/2006</ethicapprovaldate>
      <hrec>H06/035</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Jabbour</name>
      <address>Cardiology Department
Level 4 Xavier Buidling
St Vincent's Hospital
Darlinghurst NSW 2010</address>
      <phone>02 83821111</phone>
      <fax />
      <email>ajabbour@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Andrew Jabbour</name>
      <address>Cardiology Department
Level 4 Xavier Buidling
St Vincent's Hospital
Darlinghurst NSW 2010</address>
      <phone>02 83821111</phone>
      <fax />
      <email>ajabbour@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>